The purpose of this study is to evaluate the efficacy and safety of divarasib andpembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin,for the first-line treatment of adult participants with KRAS G12C-mutated, advanced ormetastatic non squamous non-small cell lung cancer (NSCLC).
The purpose of this study is to evaluate the efficacy and safety of divarasib andpembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin,for the first-line treatment of adult participants with KRAS G12C-mutated, advanced ormetastatic non squamous non-small cell lung cancer (NSCLC).
